# SLFN11

## Overview
SLFN11 is a gene that encodes the protein schlafen family member 11, which is a crucial component of the DNA damage response and cellular stress pathways. The protein is characterized by its endonuclease and helicase domains, which contribute to its role in modulating DNA repair processes and maintaining genomic stability (Metzner2022Mechanistic; Murai2019Schlafen). SLFN11 is involved in the inhibition of homologous recombination repair and the destabilization of replication protein A (RPA)-single-stranded DNA complexes, thereby influencing DNA damage checkpoints and chromatin remodeling (Mu2015SLFN; Murai2020Chromatin). Clinically, SLFN11 serves as a biomarker for sensitivity to DNA-damaging agents in cancer therapy, with its expression levels correlating with treatment outcomes in various cancers, including small cell lung cancer and ovarian cancer (Mu2015SLFN; Gardner2017Chemosensitive). The protein's interactions with other cellular components and its regulation through post-translational modifications underscore its significance in both cellular biology and clinical oncology (Zhang2021A; Malone2019Dephosphorylation).

## Structure
SLFN11 is a protein composed of 901 amino acids, featuring three main domains: an N-terminal endonuclease domain (residues 1-353), a linker domain (residues 354-576), and a C-terminal domain homologous to superfamily I (SF I) DNA/RNA helicases (residues 577-901) (Metzner2022Mechanistic). The N-terminal domain functions as an endoribonuclease, cleaving tRNA at a specific site, and is similar to SLFN13 (Murai2019Schlafen). The C-terminal domain contains Walker A and B motifs, suggesting ATPase activity, although it is locked in an autoinhibited conformation, unable to bind ATP due to steric hindrance (Metzner2022Mechanistic; Jo2022Structural).

SLFN11 forms a dimeric structure, crucial for its function, with a ring-like configuration stabilized by salt bridges and polar interactions (Metzner2022Mechanistic). The protein binds single-stranded DNA (ssDNA) with high affinity, facilitated by a positively charged patch between the helicase N- and C-lobes (Metzner2022Mechanistic). Post-translational modifications, such as phosphorylation, regulate SLFN11's activity and localization, with specific sites like S753 affecting DNA binding (Metzner2022Mechanistic; Jo2022Structural). The protein's structure and function are sensitive to its phosphorylation status, influencing its enzymatic activity (Malone2019Dephosphorylation).

## Function
SLFN11 is a protein involved in the DNA damage response and cellular stress pathways in human cells. It plays a critical role in modulating DNA repair processes and maintaining genomic stability. SLFN11 interacts with the Replication Protein A (RPA) complex, specifically binding to the RPA1 subunit, which is essential for its localization to sites of DNA damage. This interaction is crucial for the recruitment of SLFN11 to DNA damage sites and for inhibiting homologous recombination repair, a key process for maintaining genome stability (Mu2015SLFN).

SLFN11 also affects checkpoint maintenance by promoting the destabilization of the RPA-ssDNA complex, leading to the degradation of single-stranded DNA and defective checkpoint maintenance. This function is important for the regulation of DNA damage checkpoints, particularly affecting the maintenance of CHK1 and CHK2 phosphorylation after DNA damage (Mu2015SLFN).

In addition to its role in DNA damage response, SLFN11 is involved in chromatin remodeling and immediate early gene activation in response to replication stress. It enhances chromatin accessibility at active promoters and intergenic sites, facilitating the transcription of immediate early genes, which are crucial for cellular stress responses (Murai2020Chromatin).

## Clinical Significance
SLFN11 is a significant biomarker in cancer therapy, particularly in its role in enhancing sensitivity to DNA-damaging agents. Alterations in SLFN11 expression, often due to epigenetic changes like promoter hypermethylation, are associated with resistance to chemotherapy and PARP inhibitors in various cancers, including small cell lung cancer (SCLC) and colorectal cancer (CRC) (Zhang2021A; Tang2018Overcoming). In SCLC, SLFN11 expression is linked to chemosensitivity, with lower levels observed in chemoresistant models (Gardner2017Chemosensitive). The gene's expression can be modulated by epigenetic modifiers, potentially reversing resistance and enhancing treatment efficacy (Zhang2021A).

SLFN11 expression is also a predictive marker for treatment outcomes in ovarian cancer, where high expression levels correlate with increased sensitivity to cisplatin-based chemotherapy (Mu2015SLFN). In non-small-cell lung cancer (NSCLC), SLFN11 hypermethylation is associated with shorter progression-free survival, indicating its potential as a biomarker for chemotherapy response (Luan2019SLFN11). The gene's role in regulating DNA damage response and its interaction with DNA repair pathways underscore its clinical significance in predicting and managing resistance to chemotherapy across multiple cancer types (Lok2017PARP).

## Interactions
SLFN11 interacts with several proteins and nucleic acids, playing a crucial role in the DNA damage response. It binds to replication protein A (RPA), specifically the RPA1 subunit, which is essential for its recruitment to sites of DNA damage and for destabilizing the RPA-ssDNA complex. This interaction inhibits checkpoint maintenance and homologous recombination repair, making cells more sensitive to DNA-damaging agents (Mu2015SLFN). SLFN11 also interacts with the minichromosome maintenance complex component 3 (MCM3) and chromatin licensing and DNA replication factor 1 (CDT1), leading to replication arrest (Jo2022Structural).

SLFN11 is involved in the degradation of CDT1 by binding to the DDB1-CUL4 CDT2 E3 ubiquitin ligase complex, which blocks replication origin firing (Zhang2021A). It also interacts with the phosphatase PPP1CC, which is necessary for its activation through dephosphorylation at specific serine/threonine residues, particularly Ser-753 (Malone2019Dephosphorylation).

SLFN11 binds to single-stranded DNA (ssDNA) but not double-stranded DNA (dsDNA), and its dimerization is stabilized by ssDNA binding (Metzner2022Mechanistic). It also interacts with ribosomal protein S4 X-linked (RPS4X), affecting the mTOR signaling pathway and inhibiting cancer cell proliferation (Jo2022Structural).


## References


[1. (Jo2022Structural) Ukhyun Jo and Yves Pommier. Structural, molecular, and functional insights into schlafen proteins. Experimental &amp; Molecular Medicine, 54(6):730–738, June 2022. URL: http://dx.doi.org/10.1038/s12276-022-00794-0, doi:10.1038/s12276-022-00794-0. This article has 30 citations.](https://doi.org/10.1038/s12276-022-00794-0)

[2. (Tang2018Overcoming) Sai-Wen Tang, Anish Thomas, Junko Murai, Jane B. Trepel, Susan E. Bates, Vinodh N. Rajapakse, and Yves Pommier. Overcoming resistance to dna-targeted agents by epigenetic activation of schlafen 11 (slfn11) expression with class i histone deacetylase inhibitors. Clinical Cancer Research, 24(8):1944–1953, April 2018. URL: http://dx.doi.org/10.1158/1078-0432.ccr-17-0443, doi:10.1158/1078-0432.ccr-17-0443. This article has 63 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-17-0443)

[3. (Lok2017PARP) Benjamin H. Lok, Eric E. Gardner, Valentina E. Schneeberger, Andy Ni, Patrice Desmeules, Natasha Rekhtman, Elisa de Stanchina, Beverly A. Teicher, Nadeem Riaz, Simon N. Powell, John T. Poirier, and Charles M. Rudin. Parp inhibitor activity correlates with slfn11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clinical Cancer Research, 23(2):523–535, January 2017. URL: http://dx.doi.org/10.1158/1078-0432.ccr-16-1040, doi:10.1158/1078-0432.ccr-16-1040. This article has 245 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-16-1040)

[4. (Malone2019Dephosphorylation) Dane Malone, Rea M. Lardelli, Manqing Li, and Michael David. Dephosphorylation activates the interferon-stimulated schlafen family member 11 in the dna damage response. Journal of Biological Chemistry, 294(40):14674–14685, October 2019. URL: http://dx.doi.org/10.1074/jbc.ra118.006588, doi:10.1074/jbc.ra118.006588. This article has 33 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.ra118.006588)

[5. (Luan2019SLFN11) Jing Luan, Xingchun Gao, Fengrui Hu, Yuelin Zhang, and Xingchun Gou. Slfn11 is a general target for enhancing the sensitivity of cancer to chemotherapy (dna-damaging agents). Journal of Drug Targeting, 28(1):33–40, June 2019. URL: http://dx.doi.org/10.1080/1061186X.2019.1616746, doi:10.1080/1061186x.2019.1616746. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/1061186X.2019.1616746)

[6. (Murai2019Schlafen) Junko Murai, Anish Thomas, Markku Miettinen, and Yves Pommier. Schlafen 11 (slfn11), a restriction factor for replicative stress induced by dna-targeting anti-cancer therapies. Pharmacology &amp; Therapeutics, 201:94–102, September 2019. URL: http://dx.doi.org/10.1016/j.pharmthera.2019.05.009, doi:10.1016/j.pharmthera.2019.05.009. This article has 128 citations.](https://doi.org/10.1016/j.pharmthera.2019.05.009)

[7. (Mu2015SLFN) Yanhua Mu, Jiangman Lou, Mrinal Srivastava, Bin Zhao, Xin‐hua Feng, Ting Liu, Junjie Chen, and Jun Huang. <scp>slfn</scp> 11 inhibits checkpoint maintenance and homologous recombination repair. EMBO reports, 17(1):94–109, December 2015. URL: http://dx.doi.org/10.15252/embr.201540964, doi:10.15252/embr.201540964. This article has 115 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.15252/embr.201540964)

[8. (Zhang2021A) Bingnan Zhang, Kavya Ramkumar, Robert John Cardnell, Carl Michael Gay, C. Allison Stewart, Wei-Lien Wang, Junya Fujimoto, Ignacio I. Wistuba, and Lauren Averett Byers. A wake-up call for cancer dna damage: the role of schlafen 11 (slfn11) across multiple cancers. British Journal of Cancer, 125(10):1333–1340, July 2021. URL: http://dx.doi.org/10.1038/s41416-021-01476-w, doi:10.1038/s41416-021-01476-w. This article has 29 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41416-021-01476-w)

[9. (Murai2020Chromatin) Junko Murai, Hongliang Zhang, Lorinc Pongor, Sai-Wen Tang, Ukhyun Jo, Fumiya Moribe, Yixiao Ma, Masaru Tomita, and Yves Pommier. Chromatin remodeling and immediate early gene activation by slfn11 in response to replication stress. Cell Reports, 30(12):4137-4151.e6, March 2020. URL: http://dx.doi.org/10.1016/j.celrep.2020.02.117, doi:10.1016/j.celrep.2020.02.117. This article has 52 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.celrep.2020.02.117)

[10. (Gardner2017Chemosensitive) Eric E. Gardner, Benjamin H. Lok, Valentina E. Schneeberger, Patrice Desmeules, Linde A. Miles, Paige K. Arnold, Andy Ni, Inna Khodos, Elisa de Stanchina, Thuyen Nguyen, Julien Sage, John E. Campbell, Scott Ribich, Natasha Rekhtman, Afshin Dowlati, Pierre P. Massion, Charles M. Rudin, and John T. Poirier. Chemosensitive relapse in small cell lung cancer proceeds through an ezh2-slfn11 axis. Cancer Cell, 31(2):286–299, February 2017. URL: http://dx.doi.org/10.1016/j.ccell.2017.01.006, doi:10.1016/j.ccell.2017.01.006. This article has 366 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.ccell.2017.01.006)

[11. (Metzner2022Mechanistic) Felix J. Metzner, Simon J. Wenzl, Michael Kugler, Stefan Krebs, Karl-Peter Hopfner, and Katja Lammens. Mechanistic understanding of human slfn11. Nature Communications, September 2022. URL: http://dx.doi.org/10.1038/s41467-022-33123-0, doi:10.1038/s41467-022-33123-0. This article has 27 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-022-33123-0)